WO2004112700A3 - Methods and compositions for modulating amyloid precursor protein translation - Google Patents

Methods and compositions for modulating amyloid precursor protein translation Download PDF

Info

Publication number
WO2004112700A3
WO2004112700A3 PCT/US2004/018158 US2004018158W WO2004112700A3 WO 2004112700 A3 WO2004112700 A3 WO 2004112700A3 US 2004018158 W US2004018158 W US 2004018158W WO 2004112700 A3 WO2004112700 A3 WO 2004112700A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
precursor protein
amyloid precursor
compositions
protein translation
Prior art date
Application number
PCT/US2004/018158
Other languages
French (fr)
Other versions
WO2004112700A2 (en
WO2004112700A8 (en
Inventor
Jack Rogers
Sandra Payton
Steve Gullans
Jeff Randall
Satinder Sarang
Original Assignee
Gen Hospital Corp
Brigham & Womens Hospital
Jack Rogers
Sandra Payton
Steve Gullans
Jeff Randall
Satinder Sarang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Brigham & Womens Hospital, Jack Rogers, Sandra Payton, Steve Gullans, Jeff Randall, Satinder Sarang filed Critical Gen Hospital Corp
Publication of WO2004112700A2 publication Critical patent/WO2004112700A2/en
Publication of WO2004112700A8 publication Critical patent/WO2004112700A8/en
Publication of WO2004112700A3 publication Critical patent/WO2004112700A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

The invention relates to products and methods for modulating amyloid precursor protein (APP) translation and/or amyloid ß(Aß) secretion. The methods of the invention are useful to prevent and treat APP translation and/or Aß secretion-associated neurological disorders such as Alzheimer’s disease, Down’s syndrome, cerebrovascular amyloidosis, Hereditary Amyloidosis with Cerebral Hemorrhage of the Dutch Type, vascular dementia, and inclusion body myositis.
PCT/US2004/018158 2003-06-06 2004-06-07 Methods and compositions for modulating amyloid precursor protein translation WO2004112700A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47672003P 2003-06-06 2003-06-06
US60/476,720 2003-06-06

Publications (3)

Publication Number Publication Date
WO2004112700A2 WO2004112700A2 (en) 2004-12-29
WO2004112700A8 WO2004112700A8 (en) 2005-03-10
WO2004112700A3 true WO2004112700A3 (en) 2006-05-09

Family

ID=33539060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/018158 WO2004112700A2 (en) 2003-06-06 2004-06-07 Methods and compositions for modulating amyloid precursor protein translation

Country Status (1)

Country Link
WO (1) WO2004112700A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101858055B1 (en) * 2015-08-04 2018-05-15 아스테라스 세이야쿠 가부시키가이샤 Composition for ameliorating cognitive functions comprising tamsulosin
US10350226B1 (en) * 2018-06-27 2019-07-16 Joshua O. Atiba Therapy and prevention of prion protein complex infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849290A (en) * 1993-02-26 1998-12-15 The General Hospital Corporation Compounds and methods for the diagnosis, treatment and prevention of diseases of cell death
US6420351B1 (en) * 1998-04-14 2002-07-16 The General Hosptial Corporation Methods for treating neuropsychiatric disorders
US20020188012A1 (en) * 1998-01-28 2002-12-12 Bisgaier Charles Larry Method for treating Alzheimer's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849290A (en) * 1993-02-26 1998-12-15 The General Hospital Corporation Compounds and methods for the diagnosis, treatment and prevention of diseases of cell death
US20020188012A1 (en) * 1998-01-28 2002-12-12 Bisgaier Charles Larry Method for treating Alzheimer's disease
US6420351B1 (en) * 1998-04-14 2002-07-16 The General Hosptial Corporation Methods for treating neuropsychiatric disorders

Also Published As

Publication number Publication date
WO2004112700A2 (en) 2004-12-29
WO2004112700A8 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
WO2006124897A3 (en) Methods and compositions for improving cognition
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
WO2006121560A8 (en) Methods and compositions for treatment of cns disorders
WO2005061544A3 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
WO2002078766A3 (en) Combination therapy
WO2006040153A3 (en) Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists
WO2003020212A3 (en) Treatment for central nervous system disorders
CA2171882A1 (en) Inhibitors of .beta.-amyloid protein production
WO2006018850A3 (en) Compositions for treating amyloid associated diseases
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2007040650A3 (en) Apoptosis promoters
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
ATE440099T1 (en) PRODUCTION AND USE OF TETRAHYDROPYRROLO Ä3, 2-CÜPYRIDINE-4-ONE DERIVATIVES FOR THE TREATMENT OF OBESITY AND PSYCHIATRIC AND NEUROLOGICAL DISEASES
EA025746B9 (en) Compounds and their use as beta site app cleaving enzyme (bace) inhibitors
WO2006023844A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
WO2007089548A3 (en) Compounds and methods for modulating protein trafficking
CN104059013B8 (en) 1-aryl-3-azabicyclo [3.1.0] hexane: its preparation method and for treating the purposes of neuropsychiatric disorders
WO2005048935A3 (en) Methods of modulating immunity
WO2005023202A3 (en) Tumor suppressor lkb1 kinase directly activates amp-activated kinase
WO2004064836A3 (en) Treatment of diseases with alpha-7 nach receptor full agonists
WO2007058805A3 (en) Compositions and methods for treating cns disorders
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2005014814A3 (en) 5’-and 3’-capped aptamers and uses therefor
WO2006091728A3 (en) Microtubule stabilizing compounds and methods of their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

122 Ep: pct app. not ent. europ. phase